PP
LCTX icon

Paloma Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Paloma Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-251,900
Closed -$219K – 2285
2020
Q2 		$219K Buy
+251,900
New +$222K ﹤0.01% 1642
2019
Q1 		– Sell
-23,200
Closed -$21K – 1815
2018
Q4 		$21K Sell
23,200
-2,289
-9% -$3.51K ﹤0.01% 1190
2018
Q3 		$52K Buy
+25,489
New +$53.5K ﹤0.01% 1471
2018
Q2 		– Sell
-14,630
Closed -$34K – 1951
2018
Q1 		$34K Hold
14,630
– – ﹤0.01% 1873
2017
Q4 		$28K Buy
+14,630
New +$31.9K ﹤0.01% 1828

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paloma Partners's LCTX Position: Q3 2020 in Review

Paloma Partners sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 251,900 shares — an estimated $219K sold.

Paloma Partners first reported a position in LCTX in Q4 2017 and held it in 5 quarters. The position peaked at $219K in Q2 2020. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • Paloma Partners reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 251,900 Lineage Cell Therapeutics shares in Q3 2020, an estimated $219K.
  • Paloma Partners first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 5 quarters.
  • Paloma Partners's Lineage Cell Therapeutics position peaked at $219K in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.